» Articles » PMID: 20175765

Systematic Review: the Association Between Obesity and Hepatocellular Carcinoma - Epidemiological Evidence

Overview
Date 2010 Feb 24
PMID 20175765
Citations 43
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Evidence increasingly implicates obesity as an independent risk factor for different cancers. We examined such evidence for hepatocellular carcinoma.

Aim: To review the effect of increased levels of body mass index on hepatocellular carcinoma risk.

Methods: We reviewed systematically the literature examining the association between increased body mass index and hepatocellular carcinoma risk. For each identified study, relevant data were extracted and appraised.

Results: Ten cohort studies (>90 million person-years), one nested case-control study (244 cases) and two case-control studies (494 cases) were identified. Of the cohort studies, 75% of person-years related to North Americans, 15% to East Asians, and 10% to Europeans. Three cohort studies adjusted for alcohol consumption, only one cohort study adjusted for hepatitis infection status. Seven cohort studies found a positive association between obesity (body mass index > or =30 kg/m(2)) and hepatocellular carcinoma risk (relative risks ranging from 1.4 to 4.1); two reported no association; and one reported a significant inverse association for a population subgroup (relative risk = 0.7, 95% confidence interval: 0.5-0.9).

Conclusion: Although most studies did not adjust for confounders and most data relate to a single world region, the overall evidence is suggestive of an increased hepatocellular carcinoma risk in obese and overweight individuals.

Citing Articles

Risk and Prognosis of Hepatocellular Carcinoma in Mexican Americans with Type 2 Diabetes Mellitus.

Hatia R, Hwang L, Li R, Troisi C, Jalal P, Amos C J Hepatocell Carcinoma. 2025; 12:93-106.

PMID: 39867264 PMC: 11762437. DOI: 10.2147/JHC.S477141.


Impact of baseline body mass index on the long-term prognosis of advanced hepatocellular carcinoma treated with immunotherapy.

Wang Y, Pan D, Yao Z, Li Y, Qu P, Wang R World J Gastroenterol. 2024; 30(37):4132-4148.

PMID: 39474397 PMC: 11514531. DOI: 10.3748/wjg.v30.i37.4132.


The Impact of Metabolic Health and Obesity on Liver Transplant Candidates and Recipients.

Vogel A, Roediger R, von Ahrens D, Fortune B, Schwartz J, Frager S Life (Basel). 2024; 14(6).

PMID: 38929668 PMC: 11204519. DOI: 10.3390/life14060685.


Incidence and Risk Factors for Hepatocellular Carcinoma in Cirrhosis: The Multicenter Hepatocellular Carcinoma Early Detection Strategy (HEDS) Study.

Reddy K, McLerran D, Marsh T, Parikh N, Roberts L, Schwartz M Gastroenterology. 2023; 165(4):1053-1063.e6.

PMID: 37429366 PMC: 10529044. DOI: 10.1053/j.gastro.2023.06.027.


Overweight/obesity-related transcriptomic signature as a correlate of clinical outcome, immune microenvironment, and treatment response in hepatocellular carcinoma.

Feng N, Du X, Zhang Y, Jiao Z, Wu X, Yang B Front Endocrinol (Lausanne). 2023; 13:1061091.

PMID: 36714595 PMC: 9877416. DOI: 10.3389/fendo.2022.1061091.